Cataract, Mydriasis, Phacoemulsification, Pseudoexfoliation Syndrome
Conditions
Keywords
cataract surgery, phacoemulsification, pupil, dilation, mydriasis, intracameral, topical, pseudoexfoliation syndrome
Brief summary
The purpose is to determine if an intracameral solution of 0.2% tropicamide and 2% phenylephrine can dilate the pupil for cataract surgery as well as pre-operative topical 1% tropicamide and 5% phenylephrine. We will be looking at two separate groups of patients, those with and those without pseudoexfoliation syndrome. We will be looking at how each method affects the size of the pupil at the beginning and at the end of cataract surgery. In addittion, we will look at what effect the two different methods have on blood pressure and heart rate in the pre-operative, peri-operative and post-operative periods.
Interventions
PROCEDUREIntracameral injection of mydriatic agent
A mixture of 0.2 % tropicamide and 2% phenylephrine will be injected into the anterior chamber at the beginning of surgery
Sponsors
Nova Scotia Health Authority
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Ability to give consent * Greater than 18 years of age * Planned clear cornea cataract extraction and placement of foldable posterior chamber intraocular lens * No secondary procedure planned (i.e. trabeculectomy, keratectomy, corneal transplant, vitreo-retinal procedure etc.) * Systemic condition capable of undergoing topical anesthesia * No previous intraocular surgery * Pseudoexfoliation syndrome (PXF) for group 1 * No Pseudoexfoliation syndrome for group 2
Exclusion criteria
* Not fulfilling inclusion criteria * Any iris pathology including but not limited to posterior synechia, iridocorneal endothelial syndrome, corectopia, traumatic mydriasis, Horner's syndrome, Adie's pupil, cyclodialysis, iridodialysis * Previous or concurrent use of Flomax® or similar alpha-antagonist medication * Corneal pathology affecting pupil magnification or measurement (keratoconus, peripheral thinning, sclerocornea, scarring) * Uncontrolled Hypertension (greater than 170/90 on pre-operative assessment on day of surgery as measured by automated DATEX monitor)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pupil size | At beginning and completion of cataract surgery |
Secondary
| Measure | Time frame |
|---|---|
| Blood pressure | Peri-operatively |
| Heart rate | Peri-operatively |
Countries
Canada
Outcome results
None listed